Table 2.

Response to blinatumomab

	Value, n (%)
Response with blinatumomab in R/R B-cell ALL (N = 227)
CR + CRi	149 (67)
CR with MRD−	109 (49)
CR with MRD+	37 (17)
CRi	3 (1)
Partial remission	8 (4)
Nonevaluable	4 (2)
CR + CRi in Ph+ (n = 55)	41 (74.5)
CR + CRi in primary refractory (n = 55)	35 (64)
CR + CRi after salvage 1 (n = 126)	90 (71)
CR + CRi after salvage 2 (n = 51)	33 (65)
CR + CRi after early relapse (<18 months of first remission) (n = 121)	78 (64)
CR + CRi after late relapse (≥36 months of first remission) (n = 17)	12 (71)
Response to EMD (n = 10)	2 (20)
Response with blinatumomab in B-cell ALL with MRD (n = 12)
No. of patients who achieved MRD−	9 (75)